The efficacy of a single dose of 45 mg
primaquine, as a gametocytocidal agent, was assessed in Mumbai, India, among adults with uncomplicated or severe
Plasmodium falciparum malaria. All the patients investigated had been found gametocytaemic, with at least 56 gametocytes/microl blood, within the first 72 h of their illness. Those with uncomplicated
malaria, like those with severe
malaria, were randomized to receive or not receive
primaquine. All the patients were followed up for 29 days post-admission, for gametocytaemia and gametocyte viability (as determined by exflagellation). Among those with uncomplicated
malaria, six (27.3%) of the 22 who did not receive
primaquine but only one (4.2%) of the 24 who did receive the
drug, on day 4, remained gametocytaemic on day 29 (P < 0.05). Similarly, seven (31.8%) of the 22 severe cases who did not receive
primaquine but only two (9.5%) of the 21 severe cases who received the
drug, on day 8, were found gametocytaemic on day 15 (P < 0.05). While the single, 45-mg dose of
primaquine recommended by the World Health Organization was effective in clearing gametocytes from the blood of > 90% of the present cases of
malaria, > 4% of the patients with uncomplicated
malaria and > 9% of those with the severe disease continued to harbour gametocytes in their peripheral blood 29 and 15 days after taking the
primaquine, respectively.